• Product NameFulvestrant
• Brief DescriptionInhibitors
• Purification99.89%
• Biological ActivityFulvestrant is a drug treatment of hormone receptor-positive metastatic breast Y in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
• Target NameEstrogen/progestogen Receptor antagonist
• CAS No. 129453-61-8
• Calculated MW 606.77
• Formulation C32H47F5O3S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
  Pathways:Endocrinology/Hormones
  Receptor:ER
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 100 mg/mL (164.8 mM); DMSO: 100 mg/mL (164.8 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Wakeling AE, et al. Y Res, 1991, 51(15), 3867-3873.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting